Quarterly report · Q2
2689.TEDINET S100SVKV
Period2023-07-01 → 2023-12-31
Filed2024-02-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥57.5bn | 2023-07-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥110.5bn | 2022-07-01 → 2023-06-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥53.7bn | 2022-07-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥747m | 2023-07-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥854m | 2022-07-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥746m | 2023-07-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.2bn | 2022-07-01 → 2023-06-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥859m | 2022-07-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥745m | 2023-07-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥857m | 2022-07-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥486m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.4bn | 2022-07-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥548m | 2022-07-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥486m | 2023-07-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥548m | 2022-07-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥43.4bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥40.9bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥40.6bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥33.3bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥30.6bn | at 2023-06-30 | Cons. | Liabilities |
| Net assets / equity | ¥10.2bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥10.3bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥9.3bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.9bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.4bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.9bn | at 2023-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.4bn | at 2023-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.6bn | at 2022-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.1bn | at 2022-06-30d | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥146m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥660m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.9bn | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥347m | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥306m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥143m | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥1.0bn | 2023-07-01 → 2023-12-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥176m | 2022-07-01 → 2023-06-30 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.5bn | 2022-07-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥81.01 | 2023-07-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.16 | 2023-10-01 → 2023-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥234.9 | 2022-07-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥91.09 | 2022-07-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥49.24 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 23.4% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.3% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.9% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-07-01 → 2023-12-31 | −¥725m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-07-01 → 2023-12-31 | −¥725m |
| Reconciling Itemsreconciling | segment profit | 2023-07-01 → 2023-12-31 | −¥76m |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥1.3bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥1.3bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥1m |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥102m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥54.3bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥53.6bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥656m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥669m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue | 2023-07-01 → 2023-12-31 | ¥2.6bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue external | 2023-07-01 → 2023-12-31 | ¥2.5bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥68m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | segment profit | 2023-07-01 → 2023-12-31 | ¥52m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-07-01 → 2023-12-31 | ¥58.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-07-01 → 2023-12-31 | ¥57.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-07-01 → 2023-12-31 | ¥725m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-07-01 → 2023-12-31 | ¥823m |
| Reconciling Itemsreconciling | revenue | 2022-07-01 → 2022-12-31 | −¥789m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-07-01 → 2022-12-31 | −¥789m |
| Reconciling Itemsreconciling | segment profit | 2022-07-01 → 2022-12-31 | −¥71m |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥1.2bn |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥104,000 |
| jpcrp040300-q2r_E02928-000Care Nursing Goodsreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥92m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥50.7bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥50.0bn |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥726m |
| jpcrp040300-q2r_E02928-000Medical Equipmentreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥735m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue | 2022-07-01 → 2022-12-31 | ¥2.6bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue external | 2022-07-01 → 2022-12-31 | ¥2.5bn |
| jpcrp040300-q2r_E02928-000SPDreportable segment | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥64m |
| jpcrp040300-q2r_E02928-000SPDreportable segment | segment profit | 2022-07-01 → 2022-12-31 | ¥98m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-07-01 → 2022-12-31 | ¥54.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-07-01 → 2022-12-31 | ¥53.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-07-01 → 2022-12-31 | ¥789m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-07-01 → 2022-12-31 | ¥925m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 493
| Item | Context | Value | Unit |
|---|---|---|---|
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -110000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -55000000 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -181291000 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -221569000 | JPY |
| Proceeds from disposal of treasury stock fin cf | Prior1YTDDuration | 175670000 | JPY |
| Proceeds from disposal of treasury stock fin cf | CurrentYTDDuration | 1884000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -367068000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -435736000 | JPY |
| Repayments of lease obligations fin cf | Prior1YTDDuration | -83276000 | JPY |
| Repayments of lease obligations fin cf | CurrentYTDDuration | -75196000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 1534033000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 1014382000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -543279000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 521657000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 3149605000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 2359777000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 2606325000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 2881434000 | JPY |
| Allowance for doubtful accounts notes trade receivables and contract asset | Prior1YearInstant | -9863000 | JPY |
| Allowance for doubtful accounts notes trade receivables and contract asset | CurrentQuarterInstant | -12275000 | JPY |
| Allowance for doubtful accounts electronically recorded monetary claims operating ca by group | Prior1YearInstant | -1255000 | JPY |
| Allowance for doubtful accounts electronically recorded monetary claims operating ca by group | CurrentQuarterInstant | -1736000 | JPY |
| Allowance for doubtful accounts ioa by group | Prior1YearInstant | -18960000 | JPY |
| Allowance for doubtful accounts ioa by group | CurrentQuarterInstant | -19165000 | JPY |
| Payroll and allowances sga | Prior1YTDDuration | 2384063000 | JPY |
| Payroll and allowances sga | CurrentYTDDuration | 2515824000 | JPY |
| Retirement benefit expenses sga | Prior1YTDDuration | 114586000 | JPY |
| Retirement benefit expenses sga | CurrentYTDDuration | 130500000 | JPY |
| Provision for share based remuneration for directors and other officers sga | Prior1YTDDuration | 27235000 | JPY |
| Provision for share based remuneration for directors and other officers sga | CurrentYTDDuration | 25318000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 5146000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 4116000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02928-000MedicalEquipmentReportableSegmentsMember | 49968754000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02928-000SPDReportableSegmentsMember | 2503394000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E02928-000CareNursingGoodsReportableSegmentsMember | 1245944000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 53718093000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 53718093000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02928-000MedicalEquipmentReportableSegmentsMember | 725718000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02928-000SPDReportableSegmentsMember | 63531000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E02928-000CareNursingGoodsReportableSegmentsMember | 104000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 789354000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -789354000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02928-000MedicalEquipmentReportableSegmentsMember | 50694473000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02928-000SPDReportableSegmentsMember | 2566925000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E02928-000CareNursingGoodsReportableSegmentsMember | 1246048000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 54507447000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |